SCHEMBL233195

SCHEMBL233195

CN[C@@H](C)C(=O)N(CCc1ccc(Cl)c(Cl)c1)C1C2CC3CC1CC(O)(C3)C2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 3/20 0.37
XIAP P98170 1/20 0.36
BIRC2 Q13490 1/20 0.36
SIGMAR1 Q99720 6/20 0.35
LIPG Q9Y5X9 4/20 0.34
GRIN2D O15399 1/20 0.34
GRIN3B O60391 1/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2A Q12879 1/20 0.34
GRIN2B Q13224 1/20 0.34
GRIN2C Q14957 1/20 0.34
GRIN3A Q8TCU5 1/20 0.34
MAPT P10636 2/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
LMNA P02545 1/20 0.33
EPHX2 P34913 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL232420 0.77 MEN1 (0.36) HSD11B1EPHX2MEN1CYP1A2CYP2C19
SCHEMBL233343 0.74 P2RX7 (0.35) HSD11B1XIAPMAPTHTTNPSR1
SCHEMBL2828148 0.69 SIGMAR1 (0.37) HSD11B1SIGMAR1GRIN2DGRIN3BGRIN1
SCHEMBL2828153 0.69 SIGMAR1 (0.37) HSD11B1SIGMAR1GRIN2DGRIN3BGRIN1
SCHEMBL2828151 0.69 SIGMAR1 (0.37) HSD11B1SIGMAR1GRIN2DGRIN3BGRIN1
SCHEMBL17668317 0.62 HSD11B1 (0.46) HSD11B1HTTNPSR1LMNAEPHX2
SCHEMBL17668330 0.62 HSD11B1 (0.46) HSD11B1HTTNPSR1LMNAEPHX2
SCHEMBL17668316 0.62 HSD11B1 (0.46) HSD11B1HTTNPSR1LMNAEPHX2
SCHEMBL17668327 0.62 HSD11B1 (0.46) HSD11B1HTTNPSR1LMNAEPHX2
SCHEMBL17668319 0.62 HSD11B1 (0.46) HSD11B1HTTNPSR1LMNAEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9133145-B2 Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme ABBVIE INC. (US) 2015-09-15 US claimed
US-20130338169-A1 METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME ABBVIE INC. (US) 2013-12-19 US claimed
US-20130059829-A1 TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS ABBVIE INC. 2013-03-07 US claimed
US-8372841-B2 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme ABBOTT LABORATORIES (US) 2013-02-12 US claimed
US-20120004206-A1 INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME ABBVIE INC. 2012-01-05 US claimed
EP-2345640-A1 Adamantyl- acetamide derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme Abbott Laboratories (US) 2011-07-20 EP claimed
US-20110159005-A1 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF ABBOTT LABORATORIES (US) 2011-06-30 US claimed
US-20100222316-A1 INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME ABBOTT LABORATORIES (US) 2010-09-02 US claimed
US-20100152179-A9 TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS ABBOTT LABORATORIES (US) 2010-06-17 US claimed
US-20090192141-A1 METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME ABBOTT LABORATORIES (US) 2009-07-30 US claimed
US-20090054426-A1 TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS ABBOTT LABORATORIES (US) 2009-02-26 US claimed
US-20050277647-A1 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme ABBVIE INC. 2005-12-15 US claimed
US-9464072-B2 Treatment of central nervous system disorders ABBVIE INC. (US) 2016-10-11 US disclosed
US-9133145-B2 Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme ABBVIE INC. (US) 2015-09-15 US disclosed
US-20150099740-A1 TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS ABBOTT LABORATORIES 2015-04-09 US disclosed
US-8940902-B2 Treatment of central nervous system disorders ABBVIE INC. (US) 2015-01-27 US disclosed
US-20100222316-A1 INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME ABBOTT LABORATORIES (US) 2010-09-02 US disclosed
US-20100152179-A9 TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS ABBOTT LABORATORIES (US) 2010-06-17 US disclosed
US-20090192141-A1 METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME ABBOTT LABORATORIES (US) 2009-07-30 US disclosed
US-20090054426-A1 TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS ABBOTT LABORATORIES (US) 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152179-A9 TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS CHAT, HSD17B1, ACHE HSD11B1 5/4885XIAP 1904/4885BIRC2 3372/4885
US-20100222316-A1 INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885XIAP 2572/4885BIRC2 3408/4885
US-20130338169-A1 METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885XIAP 2450/4885BIRC2 3208/4885
US-20090192141-A1 METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885XIAP 2450/4885BIRC2 3208/4885
US-20050277647-A1 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885XIAP 2572/4885BIRC2 3408/4885
US-20090054426-A1 TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS CHAT, HSD17B1, ACHE HSD11B1 5/4885XIAP 1904/4885BIRC2 3372/4885
US-20150099740-A1 TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS CHAT, HSD17B1, ACHE HSD11B1 5/4885XIAP 1904/4885BIRC2 3372/4885
US-20110159005-A1 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885XIAP 1469/4885BIRC2 3283/4885
US-20120004206-A1 INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885XIAP 2572/4885BIRC2 3408/4885
US-20130059829-A1 TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS CHAT, HSD17B1, ACHE HSD11B1 5/4885XIAP 1904/4885BIRC2 3372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.